Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
Stocks Slip on Apple News, but Stay Positive for the Week
12:00am, Monday, 22'nd Jun 2020
Stocks Analysis by Zacks Investment Research covering: Vertex Pharmaceuticals Inc, Gilead Sciences Inc, Apple Inc, Rambus Inc. Read Zacks Investment Research's latest article on Investing.com
Mackenzie Financial Corp Invests $333,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
07:24am, Sunday, 21'st Jun 2020
Mackenzie Financial Corp purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the first quarter, Holdings Channel reports. The firm purchased 3,946 shares of the bio
BioMarin's Hemophilia Data, And Other News: The Good, Bad And Ugly Of Biopharma
10:46am, Friday, 19'th Jun 2020Q3 2020 Earnings Forecast for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Issued By Oppenheimer
06:20am, Friday, 19'th Jun 2020
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Oppenheimer dropped their Q3 2020 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued to investors o
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up on Analyst Upgrade
01:24am, Friday, 19'th Jun 2020
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s share price gapped up before the market opened on Thursday after SunTrust Banks raised their price target on the stock from $109.00 to $143.00. The stock
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
12:00am, Friday, 19'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 18)
ADC Therapeutics SA (NYSE:...
Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial | The Motley Fool
09:41pm, Thursday, 18'th Jun 2020
While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.
Nasdaq Beats Dow In Rangebound Trading; When To Buy These Restaurant Stocks
07:45pm, Thursday, 18'th Jun 2020
The Nasdaq leads with a small gain in late-afternoon trade. Indexes are holding in a tight, bullish range. Will these restaurant plays keep rising?
BioMarin’s hemophilia gene therapy ‘Roc solid’ after 4 years
02:57pm, Thursday, 18'th Jun 2020
Four years on, BioMarin’s hemophilia A gene therapy is still going strong—it staved off bleeding episodes in patients with hemophilia A and reduced their reliance on infusions of a blood-clotting
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG) and Amgen (NASDAQ: AMGN) - Markets
02:46pm, Thursday, 18'th Jun 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
01:44pm, Thursday, 18'th Jun 2020
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does n
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
01:04pm, Thursday, 18'th Jun 2020
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does n
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
01:01pm, Thursday, 18'th Jun 2020
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does n
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
01:00pm, Thursday, 18'th Jun 2020
There’s a pivotal trial in the offing for Pfizer and Sangamo’s hemophilia A gene therapy, but, in the meantime, the duo is unveiling updated phase 1/2 data. The highest dose of the treatment helpe
